---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-002898"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:21:07.652271+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ainos reports FY2023 revenue drop to $122K; net loss $13.8M

## Summary
- Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.
- Gross loss of $253,733 vs positive gross profit of $1.4M a year earlier; net loss $13.77M vs $14.01M.
- Cash and cash equivalents $1.89M at Dec 31, 2023, nearly flat from $1.85M at Dec 31, 2022.
- R&D expenses rose to $7.32M; SG&A fell to $5.64M on lower share-based compensation.
- Strategic pivot: advancing VELDONA Phase III, AI Nose VOC platform with NISD & Inabata, and pet supplement sales.

## SEC filing metadata
- accession: 0001654954-24-002898
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/0001654954-24-002898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/aimd_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-002898
- JSON: https://secwatch.observer/filing/0001654954-24-002898.json
- Plain text: https://secwatch.observer/filing/0001654954-24-002898.txt

## Key facts
- Earnings Releases
  Ainos, Inc. reported the year ended December 31, 2023 results: revenue US$122,112, net income US$13,770,549.
  - Period: the year ended December 31, 2023
  - Revenue: US$122,112
  - Net income: US$13,770,549
  - Result: reported results
  source text: amount of US$3 million. These transactions provided us with additional capital as we implement our growth strategy.” Full Year 2023 Financial Results Revenues Revenues were US$122,112, compared to US$3,519,627 in the full year of 2022, reflecting a decrease in selling price and sales volume of the Company's COVID-19 Antigen Rapid Test Kits attributable to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/0001654954-24-002898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.